Kulkarni Samarth 4

What Happened

• Samarth Kulkarni, CEO of CRISPR Therapeutics (CRSP), reported three open-market sales totaling 90,000 shares for aggregate proceeds of $5,166,298. Sales were: 21,433 shares at a weighted-average $51.61 ($1,106,157), 8,567 shares at a weighted-average $52.10 ($446,341), and 60,000 shares at a weighted-average $60.23 ($3,613,800). These were disposals (sales), which are generally considered routine insider liquidity events rather than buy signals.

Key Details

• Transaction dates and prices:
  • 2026-01-20: 21,433 shares — weighted avg $51.61 (prices ranged $51.00–$51.99) (Footnote F2)
  • 2026-01-20: 8,567 shares — weighted avg $52.10 (prices ranged $52.00–$52.45) (Footnote F3)
  • 2026-01-22: 60,000 shares — weighted avg $60.23 (prices ranged $60.00–$60.61) (Footnote F4)
• Aggregate proceeds: $5,166,298.
• Plan/authorization: Sales were made pursuant to a Rule 10b5-1 trading plan adopted Aug 27, 2025 (Footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing details.
• Filing timeliness: Report filed Jan 22, 2026; no late-filing indication in the provided information.

Context

• The transactions were executed under an established 10b5-1 plan, which typically schedules trades in advance and is intended to insulate insiders from trading on material nonpublic information. Sales under such plans are often routine liquidity events.